Clinicopathological characteristics and outcomes of ROS1‐rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|6|4|413-420

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.6, Iss.4, 2015-07, pp. : 413-420

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 324-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 159-163

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 228-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

Different EGFR gene mutations in two patients with synchronous multiple lung cancers: A case report

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 189-192

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 298-304

John Wiley & Sons Inc

Access to resources Recommend Favorite